Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 27;12(8):423-435.
doi: 10.4254/wjh.v12.i8.423.

Review: Pathogenesis of cholestatic liver diseases

Raquel T Yokoda  1 , Eduardo A Rodriguez  2
Affiliations
Review

Review: Pathogenesis of cholestatic liver diseases

Raquel T Yokoda et al. World J Hepatol. .

Abstract

Cholestatic liver diseases (CLD) begin to develop after an impairment of bile flow start to affect the biliary tree. Cholangiocytes actively participate in the liver response to injury and repair and the intensity of this reaction is a determinant factor for the development of CLD. Progressive cholangiopathies may ultimately lead to end-stage liver disease requiring at the end orthotopic liver transplantation. This narrative review will discuss cholangiocyte biology and pathogenesis mechanisms involved in four intrahepatic CLD: Primary biliary cholangitis, primary sclerosing cholangitis, cystic fibrosis involving the liver, and polycystic liver disease.

Keywords: Bile acid; Cholangitis; Cholestasis; Epigenomics; Immunogenetics; Pathogenesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Core pathogenic mechanism of cholestatic liver diseases.
Figure 2
Figure 2
Cholestatic liver disease clinical spectrum.
Figure 3
Figure 3
Immunogenetics related to the core of cholestatic liver diseases. PSC: Primary sclerosing cholangitis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. United Network for Organ Sharing - UNOS [Internet]. 2018. Available from: https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/
    1. Khungar V, Goldberg DS. Liver Transplantation for Cholestatic Liver Diseases in Adults. Clin Liver Dis. 2016;20:191–203. - PMC - PubMed
    1. Lazaridis KN, LaRusso NF. The Cholangiopathies. Mayo Clin Proc. 2015;90:791–800. - PMC - PubMed
    1. De Assuncao TM, Sun Y, Jalan-Sakrikar N, Drinane MC, Huang BQ, Li Y, Davila JI, Wang R, O'Hara SP, Lomberk GA, Urrutia RA, Ikeda Y, Huebert RC. Development and characterization of human-induced pluripotent stem cell-derived cholangiocytes. Lab Invest. 2015;95:684–696. - PMC - PubMed
    1. Sclair SN, Fiel MI, Wu HS, Doucette J, Aloman C, Schiano TD. Increased hepatic progenitor cell response and ductular reaction in patients with severe recurrent HCV post-liver transplantation. Clin Transplant. 2016;30:722–730. - PubMed